Table II.
A, Carcinomatous component | |||
---|---|---|---|
| |||
Antibody | Check sum | Positive | Positive rate |
FLI-1 | 1 | 1 | 100 |
Melan-A | 5 | 4 | 80 |
Vimentin | 9 | 7 | 78 |
CD56 | 4 | 3 | 75 |
Inhibin | 6 | 3 | 50 |
Ki-67 | 2 | 1 | 50 |
Syn | 7 | 3 | 43 |
NSE | 5 | 2 | 40 |
HMB-45 | 5 | 1 | 20 |
Desmin | 7 | 1 | 14 |
S-100 | 8 | 1 | 13 |
| |||
B, Sarcomatous component | |||
| |||
Antibody | Check sum | Positive | Positive rate |
| |||
HHF | 3 | 3 | 100 |
Bcl-2 | 1 | 1 | 100 |
FLI-1 | 1 | 1 | 100 |
Vimentin | 9 | 8 | 89 |
Desmin | 7 | 5 | 71 |
CD56 | 4 | 2 | 50 |
Caldesmon | 2 | 1 | 50 |
Ki-67 | 2 | 1 | 50 |
Myoglobin | 2 | 1 | 50 |
Myogenin | 5 | 2 | 40 |
NSE | 5 | 2 | 40 |
Calretinin | 5 | 1 | 20 |
Melan-A | 5 | 1 | 20 |
SMA | 6 | 1 | 17 |
Syn | 7 | 1 | 14 |
CD, cluster of differentiation; Syn, synaptophysin; NSE, neuron specific enolase; HMB-45, human melanoma black 45; SMA, smooth muscle actin.